Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma - Related Studies - ClinicalTrials.gov

Skip to Main Content

ClinicalTrials.gov

Home Search Study Topics Glossary


	Full Text View


	Tabular View


	No Study Results Posted


	Related Studies

Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma

This study has been completed.

Study NCT00060684 Information provided by Cell Therapeutics

First Received: May 9, 2003 Last Updated: September 18, 2008 History of Changes

Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:

Conditions listed in this trial

Lymphoma, Low-Grade
Lymphoma, Small Lymphocytic
Lymphoma, Mixed-Cell, Follicular

Additional conditions recognized in this trial

Leukemia, B-Cell
Leukemia, Lymphocytic, Chronic, B-Cell
Lymphoma
Lymphoma, Follicular
Lymphoma, Non-Hodgkin

More general conditions related to this trial

Immune System Diseases
Immunoproliferative Disorders
Leukemia
Leukemia, Lymphoid
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type

Interventions listed in this trial

Pixantrone (BBR 2778)
fludarabine
dexamethasone
rituximab

Additional drug interventions recognized in this trial

Dexamethasone acetate
Fludarabine monophosphate

Sponsors listed in this trial

Cell Therapeutics

Back to top of Main Content